

## Opioid Products Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NP#:	NP#: Specialty:		
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City:	State:	Zip:	Office Street Address:			
Phone:			City:	State:	State: Zip:	
Medication Information (required)						
Medication Name:			Strength:	orr (required)	Dosage Form:	
☐ Check if genericsubstitution is acceptable			Directions for Use:			
☐ Check if request is for <b>continuation of therapy</b>						
Clinical Information (required)						
Select the diagnosis below:  Pain associated with active cancer treatment or cancer not in remission  Severe, persistent chronic non-cancer pain  Document the diagnosis associated with the pain:  Sickle cell anemia  Other diagnosis:  ICD-10 Code(s):						
☐ Other diagnosis: ICD-10 Code(s):  Clinical information:						
	buprenorphine/naloxone	(Bunavail/Suboxone/Z	Zubsolv) or bup	prenorphine (Subutex)	w ithin the past two	
If <b>yes</b> to the above, is there documentation of a treatment plan showing discontinuation of buprenorphine containing Medication Assistant Treatments (MAT)? <b>Q Yes Q No</b> **Please note: Medical records (e.g., chart notes) of the above is required to be submitted along with this fax.						
Is there documentation of a current patient-prescriber opioid treatment agreement (signed within 1 year of request)?   Yes  No						
	nedication regimen preso	•	_			
If yes, provide the name of the physician and date of last visit. Name: Date:						
□ American Board □ American Board □ American Board □ American Osted	nagement specialist is be d of Anesthesiology - Pai d of Psychiatry & Neurolo d of Physical Medicine & opathic Association - Pai er has evaluated the pati y	n Management ogy - Pain Managemen Rehabilitation n Management	t			
<ul> <li>Adjuvant medications specific to causative condition including but not limited to any of the following: Antidepressants, anticonvulsants, muscle relaxants, anti-inflammatory agents</li> </ul>						

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of Future Scripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: OpioidProducts\_FS\_2019Oct-W



## Opioid Products Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE, FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED
Reauthorization
If this is a reauthorization request, answer the following:
Does the patient have pain associated with active cancer treatment, cancer not in remission, or sickle cell anemia? $\square$ Yes $\square$ No
Does the patient have severe, persistent chronic non-cancer pain?   Yes  No
If yes, document the diagnosis associated with the pain:
Is there documentation of a current patient-prescriber opioid treatment agreement (signed within 1 year of request)?   Yes  No
Is there documentation that a urine drug screen (UDS) will be performed by the prescriber within 1 year of request?   Yes  No
Medication history:
For Apadaz or Benzhydrocodone-acetaminophen, answerthe following:  Has the patient had an inadequate response to or inability to tolerate generic hydrocodone-acetaminophen AND generic oxycodone-acetaminophen?   Yes  No
For Conzip, answer the following:  Has the patient had an inadequate response to or inability to tolerate 2 generic tramadol products?   Yes  No
For Oxycontin or Oxycodone ER, answer the following:
Has the patient had an inadequate response to or inability to tolerate Xtampza ER? ☐ Yes ☐ No
For Primlev, answer the following:
Has the patient had an inadequate response to or inability to tolerate generic oxycodone-acetaminophen?   Yes  No
For brand opioids with generic equivalent requests, answer the following:  Has the patient had an inadequate response to or inability to tolerate the generic equivalent?   Yes  No
For Arymo ER, Embeda, Hysingla ER, Morphabond & Zohydro ER requests, answer the following:  Has the patient had an inadequate response to or inability to tolerate two generic opioid analgesics?   Yes No  Is there a history of or a potential for drug abuse for the patient or a member of the patient's household?   Yes No
Please list all generic opioid(s) the patient has had an inadequate response to or an inability to tolerate:
Quantity Limit and Day Supply Limit Requests:
What is the quantity requested per DAY?
Does the patient's diagnosis include acute pain?   Yes  No
Has the prescriber reviewed the patient's history in state Prescription Drug Monitoring Program website? 🗆 Yes 🗅 No
Has the prescriber counseled the patient (or the patient's representative) on risk of addiction? $\square$ Yes $\square$ No
Is the substance abuse screening done by the prescriber? <b>\bigcup Yes \bigcup No</b>
Is there documentation of a current patient-prescriber opioid treatment agreement (signed within 1 year of request)?   Yes  No
Does the requested dose and frequency exceed FDA approved dosing?   Yes  No
Is the requested dose and frequency supported by compendia?
Is there documentation indicating medical necessity for a quantity that exceeds the plan limit (e.g., GI malabsorption) or the dose cannot be achieved with commercially available clinical dosage forms? <b>U Yes U No</b>
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?
Please note: This request may be denied unless all required information is received.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of Future Scripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: OpioidProducts\_FS\_2019Oct-W